Diabetes medication reduces risk of heart failure hospitalization

News-Medical.net - 11-12

0Hl7WCdR

In the largest trial to date to assess cardiovascular outcomes for an important class of diabetes medications, researchers have found that dapagliflozin markedly reduced the risk of hospitalization for heart failure in a broad population of patients with diabetes. This benefit was seen across the study population, including in patients who did not have a history of heart attack or heart failure. Results of the Dapagliflozin Effect on CardiovascuLAR Events - Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial, sponsored by AstraZeneca, were presented by Stephen Wiviott, MD, a senior investigator in the TIMI Study Group and a cardiovascular medicine specialist at Brigham and Women's Hospital, during the American Heart Association Scientific Sessions 2018, and published simultaneously in theNew England Journal of Medicine.